The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Major Drugmakers Push Back in U.S. Price Debate

Major Drugmakers Push Back in U.S. Price Debate

January 15, 2016 • By Caroline Humer

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Explaining Price
Drugmakers keep actual pricing details close to guard their position in negotiations with commercial insurers and government health plans like Medicaid. There is no centralized catalog of U.S. list prices or rebates for medicines.

You Might Also Like
  • Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017
  • U.S. to Require Drugmakers to Show Prices in TV Ads
  • Trump Says Drug Companies to Announce “Massive” Price Cuts Soon

That drug executives at the San Francisco conference allowed even a glimpse into their actual pricing strategies reflects the intensity of the new attention being paid to their practices.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In meetings at the event, investors pressed pharmaceutical executives for more transparency about pricing, said Les Funtleyder, a portfolio manager for E Squared Asset Management, which holds shares in Pfizer and Lilly.

“What they really want to know is, are you thinking about this issue?” he said of the investors. “They are looking for an acknowledgement on the management team’s part.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

E Squared expects the new scrutiny will have an impact, projecting that drugmakers will raise U.S. list prices by 4% to 6% in 2016, less than half the rate in 2015.

The candor of some individual pharmaceutical executives follows earlier messaging by industry advocates. In a November blog post, the industry’s main lobbying group PhRMA reported that list prices grew 13% in 2014, but actual prices increased only 5%.

U.S. health insurers say that even accounting for discounts, drug prices are rising at an unsustainable rate, and they are pressuring drugmakers for cuts.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Whether it’s a gross number, or a net number, it is still astronomical,” said Daniel Hilferty, chief executive of Independence Blue Cross, which operates in Pennsylvania and New Jersey.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Pharma Co. News Tagged With: costs, Drugs, Out-of-pocket costs, Patient costs, Pfizer Inc., pharmaceutical company

You Might Also Like:
  • Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017
  • U.S. to Require Drugmakers to Show Prices in TV Ads
  • Trump Says Drug Companies to Announce “Massive” Price Cuts Soon
  • Trump Slams Drugmakers, Vows to Let U.S. States Buy Cheaper Medicines Abroad

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.